source
- Full-Life Technologies secures $150M Series D financingFull-Life Technologies announced it has raised $150 million in a Series D financing round, comprising $110 million in the main tranche and an additional $40 million. The capital is intended to adv…
- Relay Therapeutics' zovegalisib meets efficacy endpoint in Phase 2 vascular anomalies trialRelay Therapeutics reported that its PI3Kα inhibitor zovegalisib achieved the predefined efficacy threshold in a Phase 2 study of a rare genetic vascular anomaly. The data readout exceeded Wall Str…